Navigating the Enforcement Tide: Telehealth Fraud, Peptide Scrutiny, and CPOM Crackdowns

2026-07-27

Recent federal and state actions signal a critical period of intensified scrutiny for healthcare providers. From multi-million dollar telemedicine fraud takedowns to evolving FDA guidance on compounded peptides and aggressive Corporate Practice of Medicine enforcement, understanding these shifts is paramount for operational integrity.

The regulatory landscape for healthcare businesses is undergoing a profound transformation, characterized by aggressive enforcement, evolving guidance, and a clear directive from agencies to prioritize patient safety and combat fraud. From federal indictments targeting telemedicine schemes to nuanced FDA positions on compounded substances and state-level crackdowns on corporate practice of medicine, every healthcare operator must remain vigilant. TrueEval continuously monitors these developments to provide the strategic intelligence necessary to navigate this complex environment.

> For more on this topic, see our analysis: [The Compliance Crucible: Navigating Intensified Enforcement from FTC, DOJ, and DEA](/blog/compliance-crucible-ftc-doj-dea-enforcement-2026).

The DOJ's Unwavering Gaze: Intensified Telehealth Fraud Enforcement

Federal authorities are making it unequivocally clear: the flexibility afforded by telehealth during the public health emergency has concluded, and with it, any leniency towards fraudulent practices. Recent actions by the Department of Justice (DOJ) demonstrate a zero-tolerance policy for schemes that exploit remote care models for illicit gain.

> For more on this topic, see our analysis: [DEA's Intensified Scrutiny and FDA's Strategic Device Classification: A Q2 Regulatory Briefing](/blog/dea-intensified-scrutiny-fda-device-classification-q2-briefing).

In a landmark case underscoring this commitment, Dr. David Antonio Becerril was sentenced in September 2025 to 40 months imprisonment and ordered to pay $1.25 million in restitution for his role in a nationwide telemarketing conspiracy. Operating across states like Idaho and Washington, Dr. Becerril's conviction on 16 felony counts, including healthcare and wire fraud, stemmed from fraudulent telemedicine practices that defrauded Medicare. This case highlights the severe personal consequences for practitioners who lend their licenses to schemes involving medically unnecessary services or products.

Further reinforcing this federal focus, the DOJ's recent National Health Care Fraud Takedown charged an astonishing 455 defendants, targeting $1.2 billion in alleged telemedicine fraud. This sweeping action, highlighted by the Office of Inspector General (OIG), revealed schemes involving the purchase of patient data and practitioner signatures to generate fraudulent orders for unneeded medical equipment. A Florida-based medical supply company owner and chiropractor were convicted for a $30 million scheme utilizing these very tactics.

What This Means For Your Practice: Telehealth operators, medspas, dental practices, chiropractic offices, and all healthcare businesses leveraging remote services must meticulously review their billing practices, patient acquisition strategies, and medical necessity documentation. Any model that facilitates orders or prescriptions without a direct, legitimate, and documented clinical evaluation is operating under extreme risk. The focus is squarely on the integrity of the patient-provider relationship and the medical necessity of all rendered services and ordered items. Robust internal compliance audits are no longer optional but essential to mitigate civil and criminal liabilities under federal programs such as Medicare, TRICARE, and CHAMPVA.

FDA's Vigilance: From Compounding Peptides to Supply Chain Integrity

The Food and Drug Administration (FDA) continues to exert its authority over the drug supply chain and the practice of pharmacy compounding, with significant implications for a wide range of healthcare providers, particularly those in wellness, longevity, and aesthetics.

Peptides: Advisory Vote is Not Legality

One of the most closely watched developments involves the regulatory status of certain peptides widely used in compounded therapies. On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate seven specific peptides for potential inclusion on the Section 503A bulk drug substances list. The committee voted to recommend adding six peptides – BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon – while rejecting Emideltide (DSIP).

Crucially, this advisory vote is non-binding and does not confer legal status for compounding or human use. Despite a surge of misinformation, as of July 2026, peptides like BPC-157 and TB-500 are not FDA-approved and are not legally compoundable for human use. Final legality requires a formal FDA rulemaking process, which is anticipated no earlier than 2027. Selling these peptides now, especially sourcing them from

Navigating the Enforcement Tide: Telehealth Fraud, Peptide Scrutiny, and CPOM Crackdowns

The DOJ's Unwavering Gaze: Intensified Telehealth Fraud Enforcement

FDA's Vigilance: From Compounding Peptides to Supply Chain Integrity

Peptides: Advisory Vote is Not Legality

Further Reading